240 related articles for article (PubMed ID: 21177407)
1. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
[TBL] [Abstract][Full Text] [Related]
2. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
[TBL] [Abstract][Full Text] [Related]
3. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
Hayes M; Lan C; Yan J; Xie Y; Gray T; Amirkhan RH; Dowell JE
Anticancer Res; 2011 Dec; 31(12):4135-9. PubMed ID: 22199271
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
6. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
7. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer.
Yoshida S; Koga F; Kobayashi S; Ishii C; Tanaka H; Tanaka H; Komai Y; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e21-7. PubMed ID: 22414281
[TBL] [Abstract][Full Text] [Related]
8. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
Kim MK; Cho KJ; Kwon GY; Park SI; Kim YH; Kim JH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Kim SB
Eur J Cancer; 2008 Jan; 44(1):54-60. PubMed ID: 17976974
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
10. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
11. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
[TBL] [Abstract][Full Text] [Related]
12. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
13. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
[TBL] [Abstract][Full Text] [Related]
15. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma.
Ueda S; Shirabe K; Morita K; Umeda K; Kayashima H; Uchiyama H; Soejima Y; Taketomi A; Maehara Y
Ann Surg Oncol; 2011 Apr; 18(4):1204-11. PubMed ID: 21076943
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
[TBL] [Abstract][Full Text] [Related]
18. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines].
Shang XB; Yu ZT; Tang P; Zhang XZ
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2799-802. PubMed ID: 19080461
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
Sereno M; Cejas P; Moreno V; Belda-Iniesta C; López R; Nistal M; Feliu J; De Castro Carpeño J
Int J Oncol; 2012 Jun; 40(6):2104-10. PubMed ID: 22344449
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
